Please assess the completion status of the following clinical trial:

Trial Title: An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Female patients 18 years of age or older;~2. Histologically confirmed serous carcinoma or endometrioid type of endometrial carcinoma (histological documentation of recurrence is not required);~3. Recurrent or persistent progressive disease which is refractory to curative therapy or established treatments and cannot be treated with surgery or radiotherapy;~4. Measurable disease, as defined by RECIST 1.1 criteria;~5. At least one target lesion to be used to assess response, as defined by RECIST 1.1 criteria. Tumors within a previously irradiated field will be designated as non-target lesions unless previous progression is documented;~6. Availability of archived tumor tissue sample that can be used for assessment of PrR status by the central laboratory;~7. GOG (Gynecologic Oncology Group) performance status 0-2 (refer to Appendix A);~8. Calculated Glomerular filtration rate ≥ 50 mL/min;~9. Total bilirubin ≤ 2.5 times upper limit of normal (ULN);~10. AST ≤ 2.5 times ULN (≤ 5 times ULN for patients with liver metastases);~11. Alkaline phosphatase ≤ 2.5 times ULN (≤ 5 times ULN for patients with liver metastases);~12. Albumin ≥ 3.0 mg/dL;~13. Ability to take oral medication;~14. Patients able to understand the nature of the study and who are willing to give written informed consent;~15. And for Treatment Period 2 only: 1) Patients participating in Treatment Period 1 must have had disease progression after receiving at least 4 weeks of progestin therapy or 2) Patients must be determined as PrR negative status at Screening.~Exclusion Criteria:~1. Mixed histology of the tumor or evidence of tumor histology other than serous carcinoma or endometrioid type of endometrial carcinoma;~2. Concurrent systemic corticosteroid therapy;~3. Concurrent oral contraceptive use / Women of childbearing potential not using highly effective means of contraception;~4. Pregnancy confirmed by pregnancy test / Lactating women;~5. Prior therapy with hormonal progestin agents;~6. Patients who are candidates for treatment with standard chemotherapy agents (there is no limit to the number of lines of chemotherapy);~7. History of blood clot;~8. History of known bleeding disorder (i.e. disseminated intravascular coagulation or clotting factor deficiency);~9. Major surgery within 4 weeks prior to the start of the study;~10. Patients with clinically significant illnesses which, according to the Investigator, could compromise participation in the study;~11. History of other clinically active malignancies within 5 years, except for carcinoma in situ of the cervix, basal cell carcinoma, or squamous carcinoma of the skin.~12. Known hypersensitivity or idiosyncratic reaction to any of the study drugs (Sodium Cridanimod, megestrol acetate, lidocaine) and excipients;~13. Patients with known brain metastases;~14. Patients currently receiving any other investigational agents;~15. Patients currently receiving any other anticancer therapies;~16. Participation in any other clinical study within the last 4 weeks prior to the start of the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sodium Cridanimod & progestin therapy (Type: EXPERIMENTAL): Sodium Cridanimod and progestin therapy (megestrol acetate) combination

Based on this trial design, predict the completion outcome and termination type (if applicable).